Botulinum Toxin PoisoningModule information
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
References
Glossary
What's New
Patient Information
Guidelines and Systematic Reviews
References
1. Hatheway CL. Botulism: the present status of the disease. Curr Top Microbiol Immunol. 1995;195:55-75. (PMID: 8542759)
2. Centers for Disease Control and Prevention (CDC). Botulism associated with commercially canned chili sauce—Texas and Indiana, July 2007. MMWR Morb Mortal Wkly Rep. 2007;56:767-9. (PMID: 17673898)
3. Cobb SP, Hogg RA, Challoner DJ, Brett MM, Livesey CT, Sharpe RT, et al. Suspected botulism in dairy cows and its implications for the safety of human food. Vet Rec. 2002;150:5-8. (PMID: 11817867)
4. Sobel J, Tucker N, Sulka A, McLaughlin J, Maslanka S. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis. 2004;10:1606-11. (PMID: 15498163)
5. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059-70. (PMID: 11209178)
6. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med. 1998;129:221-8. (PMID: 9696731) [Full Text]
7. Treat KN, Williams JM, Furbee PM, Manley WG, Russell FK, Stamper CD Jr. Hospital preparedness for weapons of mass destruction incidents: an initial assessment. Ann Emerg Med. 2001;38:562-5. (PMID: 11679869)
8. Martin CO, Adams HP Jr. Neurological aspects of biological and chemical terrorism: a review for neurologists. Arch Neurol. 2003;60:21-5. (PMID: 12533084)
9. Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep. 2007;1:122-34. (PMID: 18388640)
10. Zilinskas RA. Iraq's biological weapons. The past as future? JAMA. 1997;278:418-24. (PMID: 9244334)
11. Arnon SS, Midura TF, Clay SA, Wood RM, Chin J. Infant botulism. Epidemiological, clinical, and laboratory aspects. JAMA. 1977;237:1946-51. (PMID: 321825)
12. Arnon SS, Midura TF, Damus K, Thompson B, Wood RM, Chin J. Honey and other environmental risk factors for infant botulism. J Pediatr. 1979;94:331-6. (PMID: 368301)
13. Koepke R, Sobel J, Arnon SS. Global occurrence of infant botulism, 1976-2006. Pediatrics. 2008;122:e73-82. (PMID: 18595978)
14. Thompson JA, Filloux FM, Van Orman CB, Swoboda K, Peterson P, Firth SD, et al. Infant botulism in the age of botulism immune globulin. Neurology. 2005;64:2029-32. (PMID: 15917401)
15. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354:462-71. (PMID: 16452558)
16. From the Centers for Disease Control and Prevention. Infant botulism—New York City, 2001-2002. JAMA. 2003;289:834-6. (PMID: 12599363)
17. Wilson R, Morris JG Jr, Snyder JD, Feldman RA. Clinical characteristics of infant botulism in the United States: a study of the non-California cases. Pediatr Infect Dis. 1982;1:148-50. (PMID: 7145727)
18. Thompson JA, Glasgow LA, Warpinski JR, Olson C. Infant botulism: clinical spectrum and epidemiology. Pediatrics. 1980;66:936-42. (PMID: 7005856)
19. Tanzi MG, Gabay MP. Association between honey consumption and infant botulism. Pharmacotherapy. 2002;22:1479-83. (PMID: 12432974)
20. Barash JR, Arnon SS. Dual toxin-producing strain of Clostridium botulinum type Bf isolated from a California patient with infant botulism. J Clin Microbiol. 2004;42:1713-5. (PMID: 15071029)
21. Werner SB, Passaro D, McGee J, Schechter R, Vugia DJ. Wound botulism in California, 1951-1998: recent epidemic in heroin injectors. Clin Infect Dis. 2000;31:1018-24. (PMID: 11049786)
22. Keller MA, Miller VH, Berkowitz CD, Yoshimori RN. Wound botulism in pediatrics. Am J Dis Child. 1982;136:320-2. (PMID: 7041622)
23. Mulleague L, Bonner SM, Samuel A, Nichols P, Khan M, Shaw S, et al. Wound botulism in drug addicts in the United Kingdom. Anaesthesia. 2001;56:120-3. (PMID: 11167471)
24. Brashear A. The botulinum toxins in the treatment of cervical dystonia. Semin Neurol. 2001;21:85-90. (PMID: 11346029)
25. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395-400. (PMID: 12167681)
26. Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998;50:1624-9. (PMID: 9633703)
27. Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol. 2007;27:303-18. (PMID: 18197811)
28. Shapiro BE, Soto O, Shafqat S, Blumenfeld H. Adult botulism. Muscle Nerve. 1997;20:100-2. (PMID: 8995590)
29. Cherington M. Clinical spectrum of botulism. Muscle Nerve. 1998;21:701-10. (PMID: 9585323)
30. Bhatia KP, Münchau A, Thompson PD, Houser M, Chauhan VS, Hutchinson M, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry. 1999;67:90-3. (PMID: 10369829)
31. Souayah N, Karim H, Kamin SS, McArdle J, Marcus S. Severe botulism after focal injection of botulinum toxin. Neurology. 2006;67:1855-6. (PMID: 17130423)
32. Klein AW. Complications and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg. 2001;20:109-20. (PMID: 11474743)
33. Koussoulakos S. Botulinum neurotoxin: the ugly duckling. Eur Neurol. 2009;61:331-42. (PMID: 19365125)
34. Maselli RA, Bakshi N. AAEM case report 16. Botulism. American Association of Electrodiagnostic Medicine. Muscle Nerve. 2000;23:1137-44. (PMID: 10883013)
35. Lindström M, Korkeala H. Laboratory diagnostics of botulism. Clin Microbiol Rev. 2006;19:298-314. (PMID: 16614251)
36. Wheeler C, Inami G, Mohle-Boetani J, Vugia D. Sensitivity of mouse bioassay in clinical wound botulism. Clin Infect Dis. 2009;48:1669-73. (PMID: 19435438)
37. MacDonald KL, Spengler RF, Hatheway CL, Hargrett NT, Cohen ML. Type A botulism from sauteed onions. Clinical and epidemiologic observations. JAMA. 1985;253:1275-8. (PMID: 3968852)
38. Davis LE, King MK. Wound botulism from heroin skin popping. Curr Neurol Neurosci Rep. 2008;8:462-8. (PMID: 18957182)
39. Johnosn EA, Montecucco C. Botulism. IN: Engl AG, ed. Handbook of Clinical Neurology: Neuromuscular Junction Disorder. 3rd series. Amsterdam:Elsevier;2008:333-68
40. Tamburin S, Zanette G. A case of oligosymptomatic botulism. The role of single-fiber EMG in early diagnosis. J Peripher Nerv Syst. 2004;9:130-1. (PMID: 15363059)
41. Zivković SA, Shipe C. Use of repetitive nerve stimulation in the evaluation of neuromuscular junction disorders. Am J Electroneurodiagnostic Technol. 2005;45:248-61. (PMID: 16457051)
42. Robinson RF, Nahata MC. Management of botulism. Ann Pharmacother. 2003;37:127-31. (PMID: 12503947)
43. Cherington M, Ryan DW. Treatment of botulism with guanidine. Early neurophysiologic studies. N Engl J Med. 1970;282:195-7. (PMID: 5409814)
44. Francisco AM, Arnon SS. Clinical mimics of infant botulism. Pediatrics. 2007;119:826-8. (PMID: 17403857)
45. Susuki K, Takahashi H, Yuki N, Ohsawa H, Hirata K, Sakata I. Guillain-Barré syndrome mimicking botulism [Letter]. J Neurol. 2001;248:720-1. (PMID: 11569908)
46. Felz MW, Swift TR, Hobbs W. Tick paralysis in the United States: a photographic review. Arch Neurol. 2000;57:1071-2. [PMID: 10891992] (PMID: 10891992)
47. Roos KL. Nonviral Infections. In: Goetz CG, Pappert EJ, eds. Textbook of Clinical Neurology. Philadelphia: WB Saunders Company; 1999:842-67.
48. Bartt R, Shannon KM. Autoimmune and Inflammatory Disorders. In: Goetz CG, Pappert EJ, eds. Textbook of Clinical Neurology. Philadelphia: WB Saunders Company; 1999.
49. Swenson JM, Thornsberry C, McCroskey LM, Hatheway CL, Dowell VR Jr. Susceptibility of Clostridium botulinum to thirteen antimicrobial agents. Antimicrob Agents Chemother. 1980;18:13-9. (PMID: 6998374)
50. Sobel J. Botulism. Clin Infect Dis. 2005;41:1167-73. (PMID: 16163636)
51. Chang GY, Ganguly G. Early antitoxin treatment in wound botulism results in better outcome. Eur Neurol. 2003;49:151-3. (PMID: 12646758)
52. Van Rynen JL, Rega PP, Budd C, Burkholder-Allen KJ. The use of negative inspiratory force by ED personnel to monitor respiratory deterioration in the event of a botulism-induced MCI. J Emerg Nurs. 2009;35:114-7. (PMID: 19285173)
53. Kongsaengdao S, Samintarapanya K, Rusmeechan S, Sithinamsuwan P, Tanprawate S. Electrophysiological diagnosis and patterns of response to treatment of botulism with neuromuscular respiratory failure. Muscle Nerve. 2009;40:271-8. (PMID: 19609915)
54. Davis LE. Botulism. Curr Treat Options Neurol. 2003;5:23-31. (PMID: 12521561)
55. Atabek ME, Yavuz H, Oran B, Karaaslan S, Erkul I. Plasmapheresis as an adjunct treatment in severe botulism [Letter]. Intensive Care Med. 2002;28:814. (PMID: 12269246)
56. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med. 1984;76:794-8. (PMID: 6720725)
57. Fagan RP, McLaughlin JB, Middaugh JP. Persistence of botulinum toxin in patients' serum: Alaska, 1959-2007. J Infect Dis. 2009;199:1029-31. (PMID: 19203262)
58. Gupta A, Sumner CJ, Castor M, Maslanka S, Sobel J. Adult botulism type F in the United States, 1981-2002. Neurology. 2005;65:1694-700. (PMID: 16344510)
59. Underwood K, Rubin S, Deakers T, Newth C. Infant botulism: a 30-year experience spanning the introduction of botulism immune globulin intravenous in the intensive care unit at Childrens Hospital Los Angeles. Pediatrics. 2007;120:e1380-5. (PMID: 18055655)
60. Brook I. Infant botulism. J Perinatol. 2007;27:175-80. (PMID: 17314986)
61. Santos JI, Swensen P, Glasgow LA. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics. 1981;68:50-4. (PMID: 7243509)
62. Sobel J, Malavet M, John S. Outbreak of clinically mild botulism type E illness from home-salted fish in patients presenting with predominantly gastrointestinal symptoms. Clin Infect Dis. 2007;45:e14-6. (PMID: 17578769)
63. Sandrock CE, Murin S. Clinical predictors of respiratory failure and long-term outcome in black tar heroin-associated wound botulism. Chest. 2001;120:562-6. (PMID: 11502659)
64. Karwa M, Bronzert P, Kvetan V. Bioterrorism and critical care. Crit Care Clin. 2003;19:279-313. (PMID: 12699324)
65. Woodruff BA, Griffin PM, McCroskey LM, Smart JF, Wainwright RB, Bryant RG, et al. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. J Infect Dis. 1992;166:1281-6. (PMID: 1431246)
66. Gottlieb SL, Kretsinger K, Tarkhashvili N, Chakvetadze N, Chokheli M, Chubinidze M, et al. Long-term outcomes of 217 botulism cases in the Republic of Georgia. Clin Infect Dis. 2007;45:174-80. (PMID: 17578775)
FAQs
The American College of Physicians is accredited by the Accreditation Council for continuing Medical Education (ACCME) to provide continuing education for physicians. The American College of Physicians designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity. Purpose: This activity has been developed for internists to facilitate the highest quality professional work in clinical applications, teaching, consultation, or research. Upon completion of the CME activity, participants should be able to demonstrate an increase in the skills and knowledge required to maintain competence, strengthen their habits of critical inquiry and balanced judgement, and to contribute to better patient care. Disclosures: Larry E. Davis, MD, FACN, FACP received honorarium from Merck & Co., provided expert testimony, received grants from the VA, NIH, and the University of New Mexico, received royalties from Fundamentals of Neurologic Disease. Deborah Korenstein, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Richard B. Lynn, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted © 2013 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.